Hospira Inc. (HSP)

[UserAlias1]

Inflectra(TM) (infliximab) patient registry -2-

Last update: 19/02/2015 6:07:11 am


There are reports of serious infections, including tuberculosis (TB), sepsis and pneumonia, in patients taking Inflectra. Some of these infections have been fatal. Patients should tell their doctors if they have had recent or past exposure to people with TB. Their doctors will evaluate them for TB and may perform tests for TB. If patients have latent (inactive) TB, their doctors should begin TB treatment before they start Inflectra. Inflectra can lower patients' ability to fight infections, so if they are prone to or have a history of infections, or develop any signs of an infection such as fever, fatigue, cough, flu-like symptoms or warm, red or painful skin while taking Inflectra, patients should tell their doctors right away. Also, patients should tell their doctors if they are scheduled to receive a vaccine or if they have lived in a region where histoplasmosis, blastomycosis or coccidioidomycosis are common.

Reports of a type of blood cancer called lymphoma in patients on Inflectra or other TNF blockers are rare, but occur more often than expected for people in general. People who have been treated for rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, or psoriatic arthritis for a long time, particularly those with highly active disease may be more prone to develop lymphoma. Cancers, other than lymphoma, have also been reported. Rarely, children and young adults who have been treated for Crohn's disease or ulcerative colitis with Inflectra in combination with azathioprine or 6-mercaptopurine have developed a rare type of lymphoma, hepatosplenic T cell lymphoma (HSTCL) that often results in death. Patients taking Inflectra or other TNF blockers may be at an increased risk for developing lymphoma or other cancers. Patients should also tell their doctors if they have had or develop lymphoma or other cancers or if they have a lung disease called chronic obstructive pulmonary disease (COPD).

Many people with heart failure should not take Inflectra; so prior to treatment they should discuss any heart condition with their doctors. Patients should tell their doctors right away if they develop new or worsening symptoms of heart failure (such as shortness of breath, swelling of ankles or feet, or sudden weight gain).

Reactivation of hepatitis B virus has been reported in patients who are carriers of this virus and are taking TNF blockers, such as Inflectra. Some of these cases have been fatal. All patients should be screened for signs of an infection and a hepatitis B expert should be consulted if a patient tests positive for hepatitis B surface antigen.

There have been rare cases of serious liver injury in people taking infliximab, some fatal. Patients should tell their doctors if they have liver problems and contact their doctors immediately if they develop symptoms such as jaundice (yellow skin and eyes), dark brown urine, right-sided abdominal pain, fever, or severe fatigue.

Blood disorders in people taking Inflectra have been reported, some fatal. Patients should tell their doctors if they develop possible signs of blood disorders such as persistent fever, bruising, bleeding, or paleness while taking Inflectra. Nervous system disorders have also been reported. Patients should tell their doctors if they have or have had a disease that affects the nervous system, or if they experience any numbness, weakness, tingling, visual disturbances or seizures while taking Inflectra.

Allergic reactions, some severe have been reported during or after infusions with infliximab. Signs of an allergic reaction include hives, difficulty breathing, chest pain, high or low blood pressure, swelling of face and hands, and fever or chills. Inflectra should not be administered to patients with known hypersensitivity to Inflectra or any component of Inflectra. Patients should tell their doctors if they have experienced a severe allergic reaction. The most common side effects of Inflectra are: viral infections, headache, upper respiratory-tract infection, sinusitis, nausea, abdominal pain, infusion-related reactions and pain.

See the Summary of Product Characteristics (also part of the EPAR) for full details.

About Hospira

Hospira, Inc. is the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars. Through its broad, integrated portfolio, Hospira is uniquely positioned to Advance Wellness(TM) by improving patient and caregiver safety while reducing healthcare costs. The company is headquartered in Lake Forest, Ill. Learn more at www.hospira.com.

The head office for Hospira in Europe, Middle East and Africa is in Hurley, UK.

Private Securities Litigation Reform Act of 1995 -- A Caution Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Hospira's biosimilars program and approval in Europe of Inflectra. Hospira cautions that these forward-looking statements are subject to risks and uncertainties, including adequate and sustained progress on the company's quality initiatives and device strategy that may cause actual results to differ materially from those indicated in the forward-looking statements. Other factors that may affect Hospira's operations and may cause actual results to be materially different from expectations include the risks, uncertainties and factors discussed under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Hospira's latest Annual Report on Form 10-K, filed with the U.S. Securities and Exchange Commission, which are incorporated by reference. Hospira undertakes no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments, except as required by law.

References

1. Gecse K, et al. Biosimilar infliximab in inflammatory bowel disease: first
interim results from a prospective nationwide observational cohort.
Abstract P314. Presented February 2015 at ECCO-ibd, Barcelona, Spain.
2. Kim J, et al. 5 year budget impact analysis of CT-P13 (infliximab) for the
treatment of Crohn's disease in UK, Italy and France. Abstract P137.
Presented February 2015 at ECCO-ibd, Barcelona, Spain.
3. The European Federation of Crohn's and Ulcerative Colitis Associations.
What is IBD? Available at:
www.efcca.org/index.php/about-efcca/what-are-ibd. Last accessed
February 2015.
4. Putrik P, Ramiro S, Kvien TK et al. Inequities in access to biologic and
synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014. Jan;
73(1): 198-206.
5. Weise M. et al. Biosimilars: what clinicians should know. Blood. 2012;
120: 5111-5117.
6. Danese S, Colombel J, Reinisch W et al. Review article: infliximab for
Crohn's disease treatment -- shifting therapeutic strategies after 10
years of clinical experience. Alimentary Pharmacology and Therapeutics.
2011; 33: 857-869.
7. EMA. Inflectra European Public Assessment Report -- Summary for the
public. EMA/402688/2013. Available at
http://www.ema.europa.eu/ema/index.jsp?curl=/pages/medicines/human/medicin
es/002778/human_med_001677.jsp. Last accessed January 2015.
8. Inflectra (infliximab). Summary of Product Characteristics. 2014.


To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/inflectra-infliximab-patient-registry-reports-interim-results-in-the-treatment-of-inflammatory-bowel-disease-300038376.html

SOURCE Hospira, Inc.

/CONTACT: European Media, Jenny Squibbs, 90TEN Healthcare, [phone], U.S. Media, Ann Fahey-Widman, Hospira, [phone], Financial Community, Karen King, Hospira, [phone], Ruth Venning, Hospira, [phone]

/Web site: http://www.hospira.com


(END) Dow Jones Newswires

February 19, 2015 06:07 ET (11:07 GMT)

[UserAlias1]

Inflectra(TM) (infliximab) patient-registry reports interim-results in-the treatment-of inflammatory-bowel-disease

Last update: 19/02/2015 6:07:11 am

-- Hungarian National Registry reports interim results following Inflectra therapy in 90 patients with Crohn's disease and ulcerative colitis

-- These data add to the growing body of evidence supporting the efficacy and safety of Inflectra treatment in inflammatory bowel disease


BARCELONA and MADRID, Spain, Feb. 19, 2015 /PRNewswire/ -- Data have been presented today on the use of Hospira's Inflectra (infliximab), the world's first approved biosimilar monoclonal antibody (mAb), at the European Crohn's and Colitis Organisation Inflammatory Bowel Diseases (ECCO-ibd) conference. Results show a comparable response in patients treated with Inflectra to that expected with the reference product, Remicade(R) (infliximab), for inducing and maintaining remission in Crohn's disease (CD) and ulcerative colitis (UC). These data add to the body of evidence supporting Inflectra's use in inflammatory bowel disease (IBD).

Results presented from the ongoing independent, prospective, nationwide study in Hungary show that for the first 90 patients, (57 with CD and 33 with UC) treated with Inflectra, reductions compared with baseline were seen in validated measures of disease activity after both two and six weeks of treatment.(1*) C-reactive protein (CRP), a marker of inflammation, was also decreased during induction therapy for UC.(1) Four of the 90 patients showed an allergic reaction to treatment, all of who had previously received anti-TNF medication.(1) The abstract can be found at: P314 Biosimilar infliximab in inflammatory bowel diseases: first interim results from a prospective nationwide observational cohort.

Professor Peter Lakatos, one of the founders and leader of the Hungarian IBD Study Group said, "The results of this study thus far have been deeply informative to confirm the clinical efficacy and safety of biosimilar infliximab following its introduction to the Hungarian market last year. The induction and maintenance of remission in patients prescribed Inflectra are exactly as we would expect to see with Remicade."

Another abstract presented at ECCO-ibd by Kim A et al. reports that the introduction of biosimilar infliximab for the treatment of CD alone could lead to savings of between EUR76 million and EUR336 million across the United Kingdom, Italy and France within five years.(2) The abstract can be found at: P137 5 year budget impact analysis of CT-P13 (Infliximab) for the treatment of Crohn's Disease in UK, Italy and France. Biologic medicines have transformed the lives of people living with debilitating inflammatory diseases such as CD and UC, chronic conditions that affect more than 2.2 million people in Europe.(3) However, these medicines are expensive and many eligible patients across Europe have been unable to access the treatments they need to fight the disease.(4) Biosimilar medicines provide a more affordable alternative to high-cost originator biologic medicines while maintaining the same quality, efficacy and safety.(5)

Dr. Paul Audhya, vice president, Medical Affairs, Europe, Middle East and Africa, Hospira, said, "The introduction of biosimilars provides an opportunity to reduce the high cost of biologic treatment, giving patients access to more affordable care without compromising on quality, safety or efficacy. The dataset collected under the nationwide registry in Hungary further validates the long-established biosimilar regulatory pathway in the EU, and in particular the principle of extrapolation, which is fundamental to the biosimilar concept."

The data reported is derived from a network of centres across Hungary and has been compiled since Inflectra entered the Hungarian market in May 2014. The study will follow individual patients with CD for a period of 108 weeks, and patients with UC for a period of 54 weeks, following induction with Inflectra.(1)

The Hungarian registry will continue to enrol patients, adding to the evaluation of Inflectra's use in IBD in a number of ongoing studies assessing safety, adherence, long-term outcomes and cost. Additional abstracts are being presented on the use of biosimilar infliximab (CT-P13) in IBD at the ECCO-ibd conference, in total assessing 272 patients, and can be found at:
-- https://www.ecco-ibd.eu/index.php/publications/congress-abstract-s/abstracts-2015.html


Infliximab is a cornerstone treatment for many inflammatory diseases, with more than 15 years of clinical data and experience.(6) Inflectra is a biosimilar version of the anti-TNF alpha blockbuster Remicade (infliximab), and is the first biosimilar mAb to be assessed and licensed by the European Commission (EC). A biosimilar developed in-line with EU requirements can be considered a therapeutic alternative to an existing biologic.(5) Inflectra was licensed by the European Commission in September 2013 for all indications of its reference product. Inflectra is licensed in adults for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), plaque psoriasis (PsO), Crohn's disease (CD) and ulcerative colitis (UC). Inflectra is also licensed in children and adolescents aged between six and 17 years for CD and UC.(7) Inflectra is available in 24 European countries.

* For CD: reduction in CD Activity Index (CDAI) score, p 0.001 compared with baseline; for UC: reduction in partial MAYO (pMAYO) score, from 6.4 to 3.7 (at week 2) and 3.6 (at week 6).

NOTES TO EDITORS:

About Inflectra(8)

Inflectra (infliximab) is a chimeric human--murine monoclonal antibody that binds with high affinity to both soluble and transmembrane forms of TNF alpha but not to lymphotoxin alpha (TNF beta). Inflectra is indicated for:

Rheumatoid arthritis

Inflectra, in combination with methotrexate, is indicated for the reduction of signs and symptoms as well as the improvement in physical function in:
-- adult patients with active disease when the response to
disease--modifying antirheumatic drugs (DMARDs), including methotrexate,
has been inadequate.

-- adult patients with severe, active and progressive disease not previously
treated with methotrexate or other DMARDs.

In these patient populations, a reduction in the rate of the progression of joint damage, as measured by X--ray, has been demonstrated.

Adult Crohn's disease

Inflectra is indicated for:
-- treatment of moderately to severely active Crohn's disease, in adult
patients who have not responded despite a full and adequate course of
therapy with a corticosteroid and/or an immunosuppressant; or who are
intolerant to or have medical contraindications for such therapies.

-- treatment of fistulising, active Crohn's disease, in adult patients who
have not responded despite a full and adequate course of therapy with
conventional treatment (including antibiotics, drainage and
immunosuppressive therapy).

Paediatric Crohn's disease

Inflectra is indicated for treatment of severe, active Crohn's disease in children and adolescents aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy; or who are intolerant to or have contraindications for such therapies. Infliximab has been studied only in combination with conventional immunosuppressive therapy.

Ulcerative colitis

Inflectra is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6--mercaptopurine (6--MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.

Paediatric ulcerative colitis

Inflectra is indicated for treatment of severely active ulcerative colitis in children and adolescents aged 6 to 17 years, who have had an inadequate response to conventional therapy including corticosteroids and 6--MP or AZA, or who are intolerant to or have medical contraindications for such therapies.

Ankylosing spondylitis

Inflectra is indicated for treatment of severe, active ankylosing spondylitis, in adult patients who have responded inadequately to conventional therapy.

Psoriatic arthritis

Inflectra is indicated for treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate.

Inflectra should be administered
-- in combination with methotrexate

-- or alone in patients who show intolerance to methotrexate or for whom
methotrexate is contraindicated.

Infliximab has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X--ray in patients with polyarticular symmetrical subtypes of the disease.

Psoriasis

Inflectra is indicated for treatment of moderate to severe plaque psoriasis in adult patients who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen ultra-violet A (PUVA).

See the Summary of Product Characteristics (also part of the EPAR) for full details.

Important Safety Information

(MORE TO FOLLOW) Dow Jones Newswires

February 19, 2015 06:07 ET (11:07 GMT)

[DewDiligence]

PFE acquires HSP for $90/sh—CC slides: #msg-110580517.

[investora2z]

Despite the downgrade of its debt by Moody's, the stock has remained strong over the past few months. It has appreciated by 25% in three months. The earnings are scheduled for July 31, and will be a risky event for the stock. This is because the stock has already appreciated significantly, and any negative surprises will not be taken too kindly. The guidance for the full fiscal is not very robust as the sales are expected to decline by 2 to 4% on a GAAP basis. This is due to the expected impact of customer sales allowances associated with the company's device strategy. The adjusted diluted earnings per share is expected to be in a range of $2.00 to $2.10. Over the long term also, the revenue growth has been tepid, and the net income has declined. It reported a net loss in the last quarters and the revenues declined by around 8.5%. Future growth in revenues will require launch of innovative products and devices. The strong competitors like Baxter International (BAX) are known for innovation, and it is important that the company delivers on this front. The R&D expenditure increased in 2012, and the company has several products in the pipeline. However, the timing and impact of the new launches remains to be seen. Medical devices / pharmaceuticals industry is heavily dependent on new launches as patent expirations lead to sudden drop in sales due to influx of generic drugs in the market. Even Hospira is expected to face this problem going forward. Even a small medical device company PLC Systems (PLCSF) has made a mark for itself based on its innovative product RenalGuard which has received US / European patents. Hospira has to deliver good numbers in the next earnings, and also improve its performance over the long term. Otherwise, it may be difficult to maintain the positive momentum.

[Penny Roger$]

~ Tuesday! $HSP ~ Q1 Earnings posted, pending or coming soon! In Charts and Links Below!

~ $HSP ~ Earnings expected on Tuesday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=HSP&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=HSP&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=HSP
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=HSP#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=HSP+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=HSP
Finviz: http://finviz.com/quote.ashx?t=HSP
~ BusyStock: http://busystock.com/i.php?s=HSP&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=HSP >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

[Penny Roger$]

<<< $HSP Links! >>> ~ MAC's Quick DD Links without the charts.



Open these links (or the ones you desire) in background tabs
http://help.opera.com/Linux/9.52/en/keyboard.html
http://lifehacker.com/263940/force-links-to-open-in-the-background


PennyStockTweets ~ http://www.pennystocktweets.com/stocks/profile/HSP


OTC Markets Company Info ~ http://www.otcmarkets.com/stock/HSP/company-info
OTC Markets Charts ~ http://www.otcmarkets.com/stock/HSP/chart
OTC Markets Quote ~ http://www.otcmarkets.com/stock/HSP/quote
OTC Markets News ~ http://www.otcmarkets.com/stock/HSP/news
OTC Markets Financials ~ http://www.otcmarkets.com/stock/HSP/financials
OTC Markets Short Sales ~ http://www.otcmarkets.com/stock/HSP/short-sales
OTC Markets Insider Disclosure ~ http://www.otcmarkets.com/stock/HSP/insider-transactions
OTC Markets Research Reports ~ http://www.otcmarkets.com/stock/HSP/research


Google Finance Summary ~ http://www.google.com/finance?q=HSP
Google Finance News ~ http://www.google.com/finance/company_news?q=HSP
Google Finance Option chain ~ http://www.google.com/finance/option_chain?q=HSP
Google Finance Financials ~ http://www.google.com/finance?q=HSP&fstype=ii#
Google Finance Historical prices Daily ~ http://www.google.com/finance/historical?q=HSP
Google Finance Historical prices Weekly ~ http://www.google.com/finance/historical?q=HSP&histperiod=weekly#


Y! < Company >
Y! Profile ~ http://finance.yahoo.com/q/pr?s=HSP+Profile
Y! Key Stat's ~ http://finance.yahoo.com/q/ks?s=HSP+Key+Statistics
Y! Headlines ~ http://finance.yahoo.com/q/h?s=HSP+Headlines
Y! Summary ~ http://finance.yahoo.com/q?s=HSP
Y! Historical Prices ~ http://finance.yahoo.com/q/hp?s=HSP+Historical+Prices
Y! Order Book ~ http://finance.yahoo.com/q/ecn?s=HSP+Order+Book
Y! Message Boards ~ http://messages.finance.yahoo.com/mb/HSP
Y! Market Pulse ~ http://finance.yahoo.com/marketpulse/HSP
Y! Technical Analysis ~ http://finance.yahoo.com/q/ta?s=HSP+Basic+Tech.+Analysis
Y! < Analyst Coverage >
Y! Analyst Opinion ~ http://finance.yahoo.com/q/ao?s=HSP+Analyst+Opinion
Y! Analyst Estimates ~ http://finance.yahoo.com/q/ae?s=HSP+Analyst+Estimates
Y! Research Reports ~ http://finance.yahoo.com/q/rr?s=HSP+Research+Reports
Y! Star Analysts ~ http://finance.yahoo.com/q/sa?s=HSP+Star+Analysts
Y! < Ownership >
Y! Major Holders ~ http://finance.yahoo.com/q/mh?s=HSP+Major+Holders
Y! Insider Transactions ~ http://finance.yahoo.com/q/it?s=HSP+Insider+Transactions
Y! Insider Roster ~ http://finance.yahoo.com/q/ir?s=HSP+Insider+Roster
Y! < Financials >
Y! Income Statement ~ http://finance.yahoo.com/q/is?s=HSP+Income+Statement&annual
Y! Balance Sheet ~ http://finance.yahoo.com/q/bs?s=HSP+Balance+Sheet&annual
Y! Cash Flow ~ http://finance.yahoo.com/q/cf?s=HSP+Cash+Flow&annual


FINVIZ ~ http://finviz.com/quote.ashx?t=HSP&ty=c&ta=0&p=d


Investorshub Trades ~ http://ih.advfn.com/p.php?pid=trades&symbol=HSP
Investorshub Board Search ~ http://investorshub.advfn.com/boards/getboards.aspx?searchstr=HSP
Investorshub PostStream ~ http://investorshub.advfn.com/boards/poststream.aspx?ticker=HSP
Investorshub Messages ~ http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=HSP
Investorshub Videos ~ http://ih.advfn.com/p.php?pid=ihvse&ihvqu=HSP
Investorshub News ~ http://ih.advfn.com/p.php?pid=news&btn=s_ok&ctl00%24sb3%24tbq1=Get+Quote&as_values_IH=&ctl00%24sb3%24stb1=Search+iHub&symbol=HSP&s_ok=OK&from_month=3&from_day=15&from_year=2012&order=desc&selsrc%5B%5D=prnca&selsrc%5B%5D=prnus&selsrc%5B%5D=zacks&selsrc%5B%5D=money2&selsrc%5B%5D=djn&selsrc%5B%5D=bw&selsrc%5B%5D=globe&selsrc%5B%5D=edgar&selsrc%5B%5D=mwus&force=1&last_ts=1331855999&p_n=1&p_count=&p_ts=1331794260


CandlestickChart ~ http://www.candlestickchart.com/cgi/chart.cgi?symbol=HSP&exchange=US


Barchart Quote ~ http://barchart.com/quotes/stocks/HSP?
Barchart Detailed Quote ~ http://barchart.com/detailedquote/stocks/HSP
Barchart Options Quotes ~ http://barchart.com/options/stocks/HSP
Barchart Technical Chart ~ http://barchart.com/charts/stocks/HSP&style=technical
Barchart Interactive Chart ~ http://barchart.com/charts/stocks/HSP&style=interactive
Barchart Technical Analysis ~ http://barchart.com/technicals/stocks/HSP
Barchart Trader's Cheat Sheet ~ http://barchart.com/cheatsheet.php?sym=HSP
Barchart Barchart Opinion ~ http://barchart.com/opinions/stocks/HSP
Barchart Snapshot Opinion ~ http://barchart.com/snapopinion/stocks/HSP
Barchart News Headlines ~ http://barchart.com/news/stocks/HSP
Barchart Profile ~ http://barchart.com/profile//HSP
Barchart Key Statistics ~ http://barchart.com/profile.php?sym=HSP&view=key_statistics


OTC: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=HSP&MarketTicker=OTC&TYP=S
NASDAQ: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=HSP&MarketTicker=NASD&TYP=S
NYSE: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=HSP&MarketTicker=NYSE&Typ=S


Marketwatch Profile ~ http://www.marketwatch.com/investing/stock/HSP/profile
Marketwatch Analyst Estimates ~ http://www.marketwatch.com/investing/stock/HSP/analystestimates
Marketwatch Historical Quotes ~ http://www.marketwatch.com/investing/stock/HSP/historical
Marketwatch Financials ~ http://www.marketwatch.com/investing/stock/HSP/financials
Marketwatch Overview ~ http://www.marketwatch.com/investing/stock/HSP
Marketwatch SEC Filings ~ http://www.marketwatch.com/investing/stock/HSP/secfilings
Marketwatch Picks ~ http://www.marketwatch.com/investing/stock/HSP/picks
Marketwatch Hulbert ~ http://www.marketwatch.com/investing/stock/HSP/hulbert
Marketwatch Insider Actions ~ http://www.marketwatch.com/investing/stock/HSP/insideractions
Marketwatch Options ~ http://www.marketwatch.com/investing/stock/HSP/options
Marketwatch Charts ~ http://www.marketwatch.com/investing/stock/HSP/charts
Marketwatch News ~ http://bigcharts.marketwatch.com/news/symbolsearch/symbolnews.asp?news=markadv&symb=HSP&sid=1795093&framed=False


The Lion ~ http://thelion.com/bin/aio_msg.cgi?cmd=search&msg=&si=1&tw=1&tt=1&rb=1&ih=1&fo=1&iv=1&yf=1&sa=1&fb=1&gg=1&symbol=HSP


Search NYSE ~ http://www.nyse.com/about/listed/lcddata.html?ticker=HSP


StockTA ~ http://www.stockta.com/cgi-bin/analysis.pl?symb=HSP&num1=567&cobrand=&mode=stock


StockHouse ~ http://www.stockhouse.com/financialtools/sn_overview.aspx?qm_symbol=HSP
StockHouse Delayed LII ~ http://www.stockhouse.com/financialtools/sn_level2.aspx?qm_page=46140&qm_symbol=HSP


AlphaTrade ~ http://tools.alphatrade.com/index.php?t1=mc_quote_module&t2=mc_quote_module2&t3=historical&template=historical2html&sym=HSP&client_id=2740&a_width=680&a_height=1000&language=english&showVol=1&chtype=8


Reuters ~ http://www.reuters.com/finance/stocks/companyOfficers?symbol=HSP.PK&WTmodLOC=C4-Officers-5


StockWatch ~ http://www.stockwatch.com/Quote/Detail.aspx?symbol=HSP®ion=U


Search NASDAQ ~ http://www.nasdaq.com/symbol/HSP
NASDAQ Divy History ~ http://www.nasdaq.com/symbol/HSP/dividend-history
NASDAQ Short Interest ~ http://www.nasdaq.com/symbol/HSP/short-interest
NASDAQ Institutional Ownership ~ http://www.nasdaq.com/symbol/HSP/institutional-holdings
NASDAQ FlashQuotes ~ http://www.nasdaq.com/aspx/flashquotes.aspx?symbol=HSP&selected=HSP
NASDAQ InfoQuotes ~ http://www.nasdaq.com/aspx/infoquotes.aspx?symbol=HSP&selected=HSP
NASDAQ After Hours Quote ~ http://www.nasdaq.com/symbol/HSP/after-hours
NASDAQ Pre-Market Quote ~ http://www.nasdaq.com/symbol/HSP/premarket
NASDAQ Historical Quote ~ http://www.nasdaq.com/symbol/HSP/historical
NASDAQ Option Chain ~ http://www.nasdaq.com/symbol/HSP/option-chain
NASDAQ Company Headlines ~ http://www.nasdaq.com/symbol/HSP/news-headlines
NASDAQ Press Releases ~ http://www.nasdaq.com/symbol/HSP/news-headlines
NASDAQ Sentiment ~ http://www.nasdaq.com/symbol/HSP/sentiment
NASDAQ Analyst Summary ~ http://www.nasdaq.com/symbol/HSP/analyst-research
NASDAQ Guru Analysis~ http://www.nasdaq.com/symbol/HSP/guru-analysis
NASDAQ Stock Report ~ http://www.nasdaq.com/symbol/HSP/stock-report
NASDAQ Competitors ~ http://www.nasdaq.com/symbol/HSP/competitors
NASDAQ Stock Consultant ~ http://www.nasdaq.com/symbol/HSP/stock-consultant
NASDAQ Stock Comparison ~ http://www.nasdaq.com/symbol/HSP/stock-comparison
NASDAQ Call Transcripts ~ http://www.nasdaq.com/symbol/HSP/call-transcripts
NASDAQ Annual Reports ~ http://www.nasdaq.com/aspx/annualreport.aspx?symbol=HSP&selected=HSP
NASDAQ Financials ~ http://www.nasdaq.com/symbol/HSP/financials
NASDAQ Revenue & Earnings Per Share (EPS) ~ http://www.nasdaq.com/symbol/HSP/revenue-eps
NASDAQ SEC Filings ~ http://www.nasdaq.com/symbol/HSP/sec-filings
NASDAQ Ownership Summary ~ http://www.nasdaq.com/symbol/HSP/ownership-summary
NASDAQ Institutional Ownership ~ http://www.nasdaq.com/symbol/HSP/institutional-holdings
NASDAQ (SEC Form 4) ~
--------- All Trades ~ http://www.nasdaq.com/symbol/HSP/insider-trades
--------- Buys ~ http://www.nasdaq.com/symbol/HSP/insider-trades/buys
--------- Sells ~ http://www.nasdaq.com/symbol/HSP/insider-trades/sells


The Motley Fool ~ http://caps.fool.com/Ticker/HSP.aspx
The Motley Fool Earnings/Growth ~ http://caps.fool.com/Ticker/HSP/EarningsGrowthRates.aspx?source=itxsittst0000001
The Motley Fool Ratios ~ http://caps.fool.com/Ticker/HSP/Ratios.aspx?source=itxsittst0000001
The Motley Fool Stats ~ http://caps.fool.com/Ticker/HSP/Stats.aspx?source=icasittab0000006
The Motley Fool Historical ~ http://caps.fool.com/Ticker/HSP/Historical.aspx?source=icasittab0000004
The Motley Fool Scorecard ~ http://caps.fool.com/Ticker/HSP/Scorecard.aspx?source=icasittab0000003
The Motley Fool Statements ~ http://caps.fool.com/Ticker/HSP/Statements.aspx?source=icasittab0000009


MSN Money ~ http://investing.money.msn.com/investments/stock-ratings?symbol=HSP


YCharts ~ http://ycharts.com/companies/HSP
YCharts Performance ~ http://ycharts.com/companies/HSP/performance
YCharts Dashboard ~ http://ycharts.com/companies/HSP/dashboard


InsideStocks Opinion ~ http://www.insidestocks.com/texpert.asp?sym=HSP&code=XDAILY
InsideStocks Profile ~ http://www.insidestocks.com/profile.asp?sym=HSP&code=XDAILY
InsideStocks Quote ~ http://www.insidestocks.com/quote.asp?sym=HSP&code=XDAILY
InsideStocks Projection ~ http://charts3.barchart.com/procal.asp?sym=HSP


Zacks Quote ~ http://www.zacks.com/stock/quote/HSP
Zacks Estimates ~ http://www.zacks.com/research/report.php?type=estimates&t=HSP
Zacks Company Reports ~ http://www.zacks.com/research/report.php?type=report&t=HSP


Knobias ~ http://knobias.10kwizard.com/files.php?sym=HSP


StockScores ~ http://www.stockscores.com/quickreport.asp?ticker=HSP


Trade-Ideas ~ http://www.trade-ideas.com/StockInfo/HSP/HOT_TOPIC.html


Morningstar ~ http://performance.morningstar.com/stock/performance-return.action?region=USA&t=HSP&culture=en-US
Morningstar Shareholders ~ http://investors.morningstar.com/ownership/shareholders-overview.html?t=HSP®ion=USA&culture=en-us
Morningstar Transcripts~ http://www.morningstar.com/earnings/NoTranscript.aspx?t=HSP®ion=USA
Morningstar Key Ratios ~ http://financials.morningstar.com/ratios/r.html?t=HSP®ion=USA&culture=en-US
Morningstar Executive Compensation ~ http://insiders.morningstar.com/trading/executive-compensation.action?t=HSP®ion=USA&culture=en-us
Morningstar Valuation ~ http://financials.morningstar.com/valuation/price-ratio.html?t=HSP®ion=USA&culture=en-us


CCBN (Thompson Reuters) ~ http://ccbn.aol.com/company.asp?client=aol&ticker=HSP


TradingMarkets ~ http://pr.tradingmarkets.com/?lid=leftPRbox&sym=HSP


OTCBB ~ http://www.otcbb.com/asp/SiteSearch.asp?Criteria=HSP&searcharea=e&image1.x=0&image1.y=0


Insidercow ~ http://www.insidercow.com/history/company.jsp?company=HSP&B1=Search%21


Forbes News ~ http://search.forbes.com/search/find?tab=searchtabgeneraldark&MT=HSP
Forbes Press Releases ~ http://search.forbes.com/search/find?&start=1&tab=searchtabgeneraldark&MT=HSP&pub=businesswire,prnewswire&searchResults=pressRelease&tag=pr&premium=on
Forbes Web ~ http://search.forbes.com/search/web?MT=UNGS&start=1&max=10&searchResults=web&tag=web&sort=null


YouTube Symbol Search ~ http://www.youtube.com/results?search_query=HSP


Buy-Ins ~ http://www.buyins.net/tools/symbol_stats.php?sym=HSP


Quotemedia ~ http://www.quotemedia.com/results.php?qm_page=47556&qm_symbol=HSP


Earnings Whispers ~ http://www.earningswhispers.com/stocks.asp?symbol=HSP

Bloomberg Snapshot ~ http://investing.businessweek.com/research/stocks/snapshot/snapshot.asp?ticker=HSP
Bloomberg People ~ http://investing.businessweek.com/research/stocks/people/people.asp?ticker=HSP

Financial Times ~ http://markets.ft.com/Research/Markets/Tearsheets/Summary?s=HSP

Investorpoint ~ http://www.investorpoint.com/ enter "HSP" and click search.

Hotstocked ~ http://www.hotstocked.com/ enter "HSP" and click search.

Raging Bull ~ http://ragingbull.quote.com/mboard/boards.cgi?board=HSP

Hoovers ~ http://www.hoovers.com/search/company-search-results/100003765-1.html?type=company&term=HSP

DD Machine ~ http://www.ddmachine.com/default.asp?m=stocktool_frame.asp?symbol=HSP

SEC Form 4 ~ http://www.secform4.com/insider/showhistory.php?cik=HSP

OTCBB Pulse ~ http://www.otcbbpulse.com/cgi-bin/pulsequote.cgi?symbol=HSP

Failures To Deliver ~ http://failurestodeliver.com/default2.aspx enter "HSP" and click search.

http://www.coordinatedlegal.com/SecretaryOfState.html

http://regsho.finra.org/regsho-Index.html

http://www.shortsqueeze.com/?symbol=HSP&submit=Short+Quote%99



DTCC (PENSON/TDA) Check - (otc and pinks) - Note ~ I did not check for this chart blast. However, I try and help you to do so with the following links.
IHUB DTCC BOARD SEARCH #1 http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18682&srchyr=2011&SearchStr=HSP
IHUB DTCC BOARD SEARCH #2: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=14482&srchyr=2011&SearchStr=HSP
Check those searches for recent HSP mentions. If HSP is showing up on older posts and not on new posts found in link below, The DTCC issues may have been addressed and fixed. Always call the broker if your security turns up on any DTCC/PENSON list.
http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18682&srchyr=2011&SearchStr=Complete+list
For a complete list see the pinned threads at the top here ---> http://tinyurl.com/TWO-OLD-FARTS



MACDlinks

[Penny Roger$]

~ Tuesday! $HSP ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $HSP ~ Earnings expected on Tuesday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=HSP&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=HSP&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=HSP
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=HSP#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=HSP+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=HSP
Finviz: http://finviz.com/quote.ashx?t=HSP
~ BusyStock: http://busystock.com/i.php?s=HSP&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=HSP >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

[$King]

HSP @ 30.26